Immunization with the Pfizer-BioNTech vaccine will be provided to all immunocompromised individuals, including children over the age of 12.
According to the Ministry of Health and Population, the vaccine will be available from 24 hospitals across the country starting on November 14.
According to Sagar Dahal, the National Immunisation Program’s chief, “Children above the age of 12 who have compromised immunity will also be administered the Pfizer-BioNTech vaccine at this time.”
Nepal received 100,620 doses of the Pfizer-BioNTech Covid-19 vaccine, which was provided by the United States through COVAX, an international vaccine sharing scheme backed by the United Nations. The vaccine was provided by the United States through COVAX.
In Nepal, this is the fourth time that a vaccine has been administered.
In the past, Nepal has relied on the AstraZeneca vaccine, which was developed by Sinopharm in China and manufactured in India, Japan, and Europe, as well as the single-shot Janssen vaccine, which was developed by Johnson & Johnson in the United States.
Dahal states that the vaccine will be administered to people suffering from renal failure, those receiving dialysis treatments, those receiving medications following organ transplantation, cancer patients, and those suffering from lung diseases.
The Pfizer shots will also be administered to those who have high blood pressure and are taking medication, as well as those who have diabetes or heart disease, as well as those who have compromised immunity for a variety of reasons, including HIV/AIDS.
This year’s vaccine will be given out at a number of locations throughout the Kathmandu Valley. These locations include Bir Hospital, Army Hospital, Civil hospital and Patan Hospital, Bhaktapur Cancer Hospital, Tribhuvan University Teaching Hospital, Shahid Gangalal National Heart Centre and Shahid Dharmabhakta National Transplant Centre Bhaktapur.
People living in Bagmati Province will also benefit from vaccinations administered at the BP Koirala Memorial Cancer Hospital in Bharatpur and the Dhulikhel Hospital in Kavre, which are both located in that province.
BP Koirala Institute of Health Sciences, Dharan; Mechi Zonal Hospital, Jhapa; and Koshi Hospital are among the locations where the vaccine will be administered in Province 1. The vaccine will be administered in Province 2 at the Gajendra Narayan Singh Hospital, the Janakpur Hospital, and the Narayani Hospital.
The vaccine will be administered at the Gandaki Academy of Health Sciences in Baglung, as well as the Dhaulagiri Hospital in Baglung, in Gandaki Province. It will be administered at Lumbini Provincial Hospital in Butwal, Rapti Academy of Health Sciences in Dang, and Bheri Hospital in Banke in the province of Province 5.
The vaccine will be administered at Province Hospital in Surkhet in Karnali Province, and at Seti Provincial Hospital in Dhangadhi and Dadeldhura Hospital in Sudurpaschim Province. In Karnali Province, the vaccine will be administered at Province Hospital in Surkhet, and in Sudurpaschim Province, the vaccine will be administered at Province Hospital in Surkhet.
In his statement, Dahal stated that all preparations for distributing the vaccine have been completed.
The mRNA-based Covid-19 vaccine developed by Pfizer-BioNTech will be used in Nepal for the first time. An immune response is elicited by a copy of a molecule known as messenger RNA (mRNA), which was developed in collaboration by the pharmaceutical company Pfizer and the German company BioNTech.
According to the manufacturer, the Pfizer-BioNTech vaccine was 95 percent effective at preventing laboratory-confirmed infection with the coronavirus in humans.
It was also found that the Pfizer-BioNTech vaccine was highly effective at preventing laboratory-confirmed Covid-19 infection in adolescents between the ages of 12 and 15 years old, and that the immune response in these adolescents was at least as strong as the immune response in adolescents between the ages of 16 and 25 years old in clinical trials.
In a statement on its website, the US Centers for Disease Control and Prevention stated that “evidence shows mRNA Covid-19 vaccines provide similar protection in real-world conditions as they have in clinical trial settings—reducing the risk of Covid-19, including severe illness, by 90 percent or more among people who are fully vaccinated.”
The Ministry of Health is also preparing to ask the Cabinet for permission to purchase 6 million doses of the Pfizer-BioNTech Covid-19 vaccine, which was developed in collaboration with BioNTech.
According to the government’s new vaccination plan, which includes children between the ages of 12 and 18 years, Nepal needs to vaccinate approximately 78 percent of its 30 million population—or approximately 25 million people. In the past, the government had intended to vaccinate only those who were 15 years old or older.
Due to the estimated presence of 4-5 million people living abroad, the government estimates that it will need to vaccinate approximately 19-20 million people. In order to accomplish this, the country will require slightly more than 40 million doses of double-shot vaccines.
A total of 10 million doses of the Vero Cell vaccine from China have already been purchased by the government. With the help of a cost-sharing arrangement, a contract has been reached with COVAX to purchase 9.9 million doses of vaccine (5.9 million doses of Vero Cell and 4 million doses of Moderna vaccine).
As of Tuesday, a total of 6,709,905 people (22.1 percent of the total population) had received a full course of vaccination.
Up to this point, Nepal has received a total of 18,958,210 doses of vaccines from Vero Cell, AstraZeneca, Johnson and Johnson, and pfiZer-BioNTech.